Association of ALK fusion and the main clinico-pathological and molecular features. Summary of the major clinico-pathological characteristics of patients and RNA quality information and ALK, EGFR and KRAS status. (XLSX 14 kb
Additional file 1: Supplementary Figure 1. Summary of transcriptomic profiles. (A) The percentage of...
- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-...
Table S1. Information of primers and oligonucleotides used in this study. (DOCX 16 kb
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are re...
Figure S1. RT-PCR analysis of ALK, RET, or ROS1 fusion in 37 cancer cell lines. The mRNA expression ...
Figure S5. RT-PCR analysis of ALK, RET, or ROS1 fusion in 4 tumor tissues. The mRNA expression of va...
Platform and Gene-list for the Multiplex Genotyping of Circulating Tumor DNA. (DOC 45 kb
Table S1. RT-PCR Targets within the Ion AmpliSeq™ Lung Fusion Research Panel. A list of all targets ...
Table S1. RNA-sequencing results for tumor tissue (a) or non-malignant lung tissue (b). Differential...
Figure S2. Summary of ALK, RET, or ROS1 fusion in 37 cancer cell lines. Plot of normalized values ca...
Figure S6. Summary of ALK, RET, or ROS1 fusion in 4 tumor tissue specimens. Plot of normalized value...
Table S1. Reaction mixtures. (A) Screening assay. (B) Mutant specific assay. Table S2. Thermal cycli...
Figure S11. Western blotting analysis in five cancer cell lines without any fusion gene. Cell lysate...
Figure S10. Western blotting analysis in a cancer cell line with ROS1 fusion. Cell lysates were harv...
Figure S1. Distribution of RNA types from de novo RNA analysis pipeline for primary NHL and normal B...
Additional file 1: Supplementary Figure 1. Summary of transcriptomic profiles. (A) The percentage of...
- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-...
Table S1. Information of primers and oligonucleotides used in this study. (DOCX 16 kb
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are re...
Figure S1. RT-PCR analysis of ALK, RET, or ROS1 fusion in 37 cancer cell lines. The mRNA expression ...
Figure S5. RT-PCR analysis of ALK, RET, or ROS1 fusion in 4 tumor tissues. The mRNA expression of va...
Platform and Gene-list for the Multiplex Genotyping of Circulating Tumor DNA. (DOC 45 kb
Table S1. RT-PCR Targets within the Ion AmpliSeq™ Lung Fusion Research Panel. A list of all targets ...
Table S1. RNA-sequencing results for tumor tissue (a) or non-malignant lung tissue (b). Differential...
Figure S2. Summary of ALK, RET, or ROS1 fusion in 37 cancer cell lines. Plot of normalized values ca...
Figure S6. Summary of ALK, RET, or ROS1 fusion in 4 tumor tissue specimens. Plot of normalized value...
Table S1. Reaction mixtures. (A) Screening assay. (B) Mutant specific assay. Table S2. Thermal cycli...
Figure S11. Western blotting analysis in five cancer cell lines without any fusion gene. Cell lysate...
Figure S10. Western blotting analysis in a cancer cell line with ROS1 fusion. Cell lysates were harv...
Figure S1. Distribution of RNA types from de novo RNA analysis pipeline for primary NHL and normal B...
Additional file 1: Supplementary Figure 1. Summary of transcriptomic profiles. (A) The percentage of...
- Patients with non-small cell lung cancer harboring ALK receptor tyrosine kinase ( ALK), ROS proto-...
Table S1. Information of primers and oligonucleotides used in this study. (DOCX 16 kb